Drug Trial Radar · NCT05422482
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ
Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 20, 2022
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug
Conditions
- Mucopolysaccharidosis II
- Hunter Syndrome
Interventions
GC1123Biological
ICV-administered Hunterase, Idursulfase-ß
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and frequency of serious adverse events (SAEs)Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
- Frequency and characteristics (severity, outcome, etc.) of adverse eventsTime frame: Every 28 days from Week 1 through study completion (about 110 weeks)
- Presence of clinically significant abnormal echocardiography resultsTime frame: Week 1 to Phase I study completion (about 26 weeks)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Pusan National University Yangsan Hospital
Pusan, South Korea
Seoul National University
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.